Skip to main content

Dr. Adam Robinson - Senior Manager, 14C Enabled Drug Development, Scientific Consulting

Adam Robinson

Dr. Adam Robinson

Senior Manager, 14C Enabled Drug Development, Scientific Consulting

About

Dr. Adam Robinson-Miller has more than a decade of experience in the pharmaceutical and OTC environments, with particular focus on formulation design, DoE and QbD strategies for innovative drug products. More recently Dr Robinson-Miller has become one of our established SME’s in the design of Human Mass Balance or ADME studies, supporting Biotechs and Large Pharma with their ADME strategy.

Over the course of his career, Adam has worked across multiple drug modalities and across the globe to support new medicines to market.

Adam also was a guest lecturer at Hull University for the Masters in Pharmacology and Drug Development.

Adam holds an MChem in Chemistry with Medicinal Chemistry from Newcastle University, and a PhD in Chemistry from Northumbria University.

Thierry Van Nieuwenhove on the Future of CDMO Partnerships

News & Announcements , Articles & Publications , Thierry Van Nieuwenhove

Thierry Van Nieuwenhove on the Future of CDMO Partnerships

icon 6

Thierry Van Nieuwenhove, CEO of Quotient Sciences, discusses the evolving landscape of Contract Development and Manufacturing Organizations (CDMOs).

Thierry emphasizes the shift in CDMO relationships with pharma and biotech clients from transactional models to more integrated, collaborative partnerships. This shift is not just about accelerating processes for speed but about creating a more controlled and responsive drug development process.

CDMOs that offer integrated services, and a collaborative approach are better positioned to help clients navigate uncertainty and use resources efficiently. Quotient Sciences uses its Translational Pharmaceutics® platform to enable greater agility by breaking down silos between traditionally separate functions.

Read the full article on the 247biopharma website.

In Vitro and Clinical Evaluations of UGT1A1-, P-gp-, OATP1B1-, and BCRP-Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

Peer Reviewed Publication , Clinical Pharmacology

In Vitro and Clinical Evaluations of UGT1A1-, P-gp-, OATP1B1-, and BCRP-Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor

17 December 2024
Overview

Belumosudil is an oral selective rho-associated coiled-coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft-versus-host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.

In vitro assessments suggested that belumosudil may inhibit uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), P-glycoprotein (P-gp), organic anion transporting polypeptide 1B1 (OATP1B1), and breast cancer resistance protein (BCRP), resulting in drug–drug interactions (DDIs)

Download this three-part clinical DDI study (NCT05806567) to find out the effects of multiple doses of belumosudil (200 mg daily) on the single-dose pharmacokinetics of raltegravir (UGT1A1-sensitive substrate), dabigatran etexilate (P-gp-sensitive substrate), and rosuvastatin calcium (OATP1B1/BCRP-sensitive substrate).

 

Download
Date
17 December 2024

How an Integrated Approach to Project Management Helps Advance Drug Development: A Look into Quotient Sciences’ Project Management Function

Project Management , Translational Pharmaceutics

How an Integrated Approach to Project Management Helps Advance Drug Development: A Look into Quotient Sciences’ Project Management Function

How an Integrated Approach to Project Management Helps Advance Drug Development: A Look into Quotient Sciences' Project Management Function

Across the pharmaceutical industry, the R&D process is not getting any easier. Companies are faced with challenging budgets and economic pressures, all while aggressive timelines to get new therapies to market to meet patient expectations continue. 

This environment has led to increased reliance on partner CRO and CDMO companies to access the necessary services and scientific skills, knowledge, and innovation to remain ahead of competition — making the selection of a trusted, experienced partner even more important. 

At Quotient Sciences, project management is central to every drug development program that we work on. No matter where the project is performed — whether it is a clinical pharmacology program or an integrated Translational Pharmaceutics® program that combines pharmaceutical sciences and clinical capabilities into a single program of work at either of our Phase I clinical units in Miami, FL or Nottingham, UK — our project managers help ensure customers have a consistent experience and maintain high standards of quality in project delivery. 

How we approach project management for drug programs 

Our approach to project management is focused on the needs of our customers, and our project managers act as advocates to ensure an on-time and successful project delivery. Our delivery through high-performing multidisciplinary teams is fundamental to project success. Each project manager helps integrate services across scientific functions, facilities, and vendor partners to coordinate a program as it progresses from milestone to milestone. Each customer benefits from a single point of contact who will partner them from project initiation through delivery and reporting, facilitating seamless transitions to subsequent development stages. 

Our project managers are organized to lead cross-functional, multidisciplinary teams structure that provides consistency and accountability for the delivery of projects. Every customer has a dedicated project team, which provides continuity of interactions and accountability, direct peer-to-peer communication with technical experts, and program oversight to effectively manage time, cost, and quality.  

All project teams are assigned a lead team member from each of Quotient Sciences’ functions. This ranges from formulation development and manufacturing to analytical development and product release, clinical operations, regulatory and quality, and data sciences. Additionally, pharma project managers work closely with our business development and scientific teams to ensure a smooth handover to operations and continued scientific support throughout your study.  

They are also skilled at vendor management for third party services which may be required for the study, this takes some of the complexity and burden of managing multiple vendors off the customer and ensures a streamlined approach to clinical delivery.  

Our agile, adaptive project managers embrace changing requirements while always looking ahead on how to best handle complex processes. For example, real time human PK data can sometimes take us in a direction we hadn’t anticipated. Our project managers can work with multiple functions such as formulation development, analytical, regulatory, manufacturing, screening, and clinical and medical teams to ensure that any amendments to the study design, formulations or exposure limits are managed in a smooth and compliant fashion with minimal impact to project delivery timelines. 

Through effective scheduling, forecasting, and risk management, we aim to successfully develop products and expedite the delivery of new medicines to patients. 

Picture 

Project managers act as a central point of coordination, maintaining clear lines of communication and providing direct access to the individuals responsible for delivering each component of the program. As many of our project managers have joined the Project Management team via other operational departments in the business, they bring with them insider knowledge on how to get the best from the operational teams. 

Above all, the customer is put at the center of our collaborative structure to ensure project continuity and milestones are met without delay. We strive to understand the customer’s way of working, their objectives, and needs and we appreciate the huge responsibility and opportunity being bestowed on us to support their drug program. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. 

With over 200 years of combined experience and hundreds of active programs in motion, our Project Management team is well-versed in navigating the challenges that come with early-phase development. A strong focus on planning, risk mitigation, and problem-solving has earned the trust of customers — more than 98% of whom choose to partner with us again. That repeat engagement reflects not only a high standard of execution, but also the confidence clients place in the teams leading their programs.

Customer feedback about our Project Management team:

  • “I wanted to take a moment to thank you guys for helping us get the first patients dosed! Because of you we were covered in the London Times and STAT news this morning.”
  • “Quotient PM is exceptional, one of a kind!! We couldn’t have asked for more.”
  • “Excellent services, will definitely work with Quotient in future and highly recommend to contract Quotient for an excellent delivery on overall project timelines, cost, and quality.”
  • “Thanks everyone at the Quotient team... we really could not have done this without you!”
  • “Excellent support from the PM throughout the study until close out.”
  • “Excellent! ...... Having her coordinate all the teams we can see the value she brings to the whole study.”
  • “(PM) is very good at identifying risks and mitigating them. She did this without having to consult with us which was great.” 

Contact us today to learn how our project management teams can help you minimize risks and simplify the drug development process.  

CRS 2025 Annual Meeting & Exposition Pre-meeting Workshop: Recent Advances in Oral Peptide Delivery – From Molecule to Market

CRS 2025 Annual Meeting & Exposition Pre-meeting Workshop: Recent Advances in Oral Peptide Delivery – From Molecule to Market

Philadelphia, PA 19107, United States | 14 July 2025
Overview

Join Quotient Sciences along with industry leaders to hear latest insight in oral peptide development and clinical testing.

Systemic delivery of peptides by the oral route is now a reality with multiple products on the market and many more in development. Attendees will learn of the latest advances in oral peptide delivery and its future directions from world leading academics and industry leaders who have successfully taken oral peptide products from preclinical development to translation into the clinic and market launch. Topics covered include fundamental mechanisms, peptide engineering, oral peptide biopharmaceutics, novel drug delivery systems and their clinical development. Insights and learnings will be shared on how to navigate the unique challenges oral peptide programs present and future directions of the field.

Goals and Objectives

• Learn the latest developments in our understanding of oral peptide biopharmaceutics

• Hear the latest progress on the clinical development of oral products from industry leaders

• Share insights and learnings in managing the transition from preclinical to clinical development of oral peptide products

Chairs & Company Sponsors

  • Andy Lewis, Chief Scientific Officer, Quotient Sciences
  • Stephen Buckley, Vice President, Drug Product Research, Novo Nordisk
  • David Brayden, Professor of Advanced Drug Delivery, University College Dublin
DateLocation
Monday, July 14th, 2025
Time: 8:00 AM - 4:30 PM
Pennsylvania Convention Center
1101 Arch Street
Philadelphia, PA 19107

*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.

Register for the workshop:
Register
Location
Pennsylvania Convention Center
1101 Arch Street
Philadelphia, PA 19107, United States
Subscribe to